Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lewis M Watkins

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Clinical Science (London, England : 1979)|March 20, 2024
The complement system in neurodegenerative diseasesJacqui Nimmo, Robert A J Byrne, Nikoleta Daskoulidou, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2018
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59Wioleta M Zelek, Lewis M Watkins, Owain W Howell, et al.
Journal of Neuroinflammation|June 24, 2016
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsLewis M Watkins, James W Neal, Sam Loveless, et al.
Frontiers in Cellular Neuroscience|April 10, 2023
Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosisRhian Evans, Lewis M Watkins, Kristen Hawkins, et al.
Brain Pathology (Zurich, Switzerland)|February 8, 2022
The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcomeBenjamin J Cooze, Matthew Dickerson, Rukshikah Loganathan, et al.
Brain, Behavior, and Immunity|March 20, 2025
The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humansRobert A J Byrne, Jacqui Nimmo, Megan Torvell, et al.
Annals of Neurology|October 27, 2018
Meningeal inflammation and cortical demyelination in acute multiple sclerosisRyan J Bevan, Rhian Evans, Lauren Griffiths, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Clinical Science (London, England : 1979)|March 20, 2024
The complement system in neurodegenerative diseasesJacqui Nimmo, Robert A J Byrne, Nikoleta Daskoulidou, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 10, 2018
Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59Wioleta M Zelek, Lewis M Watkins, Owain W Howell, et al.
Journal of Neuroinflammation|June 24, 2016
Complement is activated in progressive multiple sclerosis cortical grey matter lesionsLewis M Watkins, James W Neal, Sam Loveless, et al.
Frontiers in Cellular Neuroscience|April 10, 2023
Complement activation and increased anaphylatoxin receptor expression are associated with cortical grey matter lesions and the compartmentalised inflammatory response of multiple sclerosisRhian Evans, Lewis M Watkins, Kristen Hawkins, et al.
Brain Pathology (Zurich, Switzerland)|February 8, 2022
The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcomeBenjamin J Cooze, Matthew Dickerson, Rukshikah Loganathan, et al.
Brain, Behavior, and Immunity|March 20, 2025
The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humansRobert A J Byrne, Jacqui Nimmo, Megan Torvell, et al.
Annals of Neurology|October 27, 2018
Meningeal inflammation and cortical demyelination in acute multiple sclerosisRyan J Bevan, Rhian Evans, Lauren Griffiths, et al.
Pageof 1